Literature DB >> 11529691

L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits.

M M Sayed-Ahmed1, M M Khattab, M Z Gad, N Mostafa.   

Abstract

This study has been initiated to investigate, in hypercholesterolaemic rabbits, whether L-carnitine deficiency could be an additional risk factor in atherosclerosis, and if so, whether L-carnitine supplementation could prevent the progression of atherosclerosis. Hypercholesterolaemia was induced by feeding rabbits 2% cholesterol-enriched diet for 28 days, whereas, carnitine deficiency was induced by daily i.p. administration of 250 mg kg(-1) of D-carnitine for 28 days. Histopathological examination of aorta and coronaries from hypercholesterolaemic rabbits revealed severe atherosclerotic lesions, intimal plaques and foam cell formation. Also, hypercholesterolaemic diet resulted in a significant 53 and 43% decrease in reduced glutathion (GSH) levels and a significant (1.87-fold) and (14.1-fold) increase in malonedialdhyde (MDA) levels in aorta and cardiac tissues, respectively. Daily administration of L-carnitine (250 mg kg(-1)) for 28 days, completely prevented the progression of atherosclerotic lesions induced by hpercholesterolaemia in both aorta and coronaries. Conversely, daily administration of D-carnitine (250 mg kg(-1)) for 28 days increased the progression of atherosclerotic lesions with the appearance of foam cells and apparent intimal plaques which are even larger than that seen in hypercholesterolaemic rabbits. Both L-carnitine and D-carnitine produced similar effects on the lipid profile, GSH and MDA which may point to the conclusion that: (1) L-carnitine prevents the progression of atherosclerotic lesions by another mechanism in addition to its antioxidant and lipid-lowering effects; (2) endogenous carnitine depletion and/or carnitine deficiency should be viewed as an additional risk factor in atherogenesis. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529691     DOI: 10.1006/phrs.2001.0852

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  15 in total

1.  Systemic antioxidant properties of L-carnitine in two different models of arterial hypertension.

Authors:  Alfonso Mate; José L Miguel-Carrasco; María T Monserrat; Carmen M Vázquez
Journal:  J Physiol Biochem       Date:  2010-05-27       Impact factor: 4.158

Review 2.  Nature and nurture in atherosclerosis: The roles of acylcarnitine and cell membrane-fatty acid intermediates.

Authors:  Harry C Blair; Jorge Sepulveda; Dionysios J Papachristou
Journal:  Vascul Pharmacol       Date:  2015-06-30       Impact factor: 5.773

3.  Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.

Authors:  Kei Fukami; Sho-Ichi Yamagishi; Kazuko Sakai; Yusuke Kaida; Takeki Adachi; Ryotaro Ando; Seiya Okuda
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

4.  Progression of cyclophosphamide-induced acute renal metabolic damage in carnitine-depleted rat model.

Authors:  Mohamed M Sayed-Ahmed
Journal:  Clin Exp Nephrol       Date:  2010-07-23       Impact factor: 2.801

5.  L-carnitine and taurine synergistically inhibit the proliferation and osteoblastic differentiation of vascular smooth muscle cells.

Authors:  Hui Xie; Bing Yang; Xin-min Zhou; Feng-lin Song; Jian-ming Li; Kang Zhou; Wen Hu; Yi-qun Peng; Si-yuan Tang; Ling-qing Yuan; Si-yuan Xiong; Xiao-bo Liao
Journal:  Acta Pharmacol Sin       Date:  2010-02-15       Impact factor: 6.150

6.  Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats.

Authors:  Salim S Al-Rejaie; Abdulaziz M Aleisa; Abdulaziz A Al-Yahya; Saleh A Bakheet; Abdulmalik Alsheikh; Amal G Fatani; Othman A Al-Shabanah; Mohamed M Sayed-Ahmed
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

7.  Does L-carnitine improve endothelial function in hemodialysis patients?

Authors:  Mohammad Reza Sabri; Farnaz Fahimi; Soheila Hajialiasgar; Abbas Etminan; Sarir Nazemi; Farzaneh Salehi
Journal:  J Res Med Sci       Date:  2012-05       Impact factor: 1.852

8.  Metabolomics with LC-QTOF-MS permits the prediction of disease stage in aortic abdominal aneurysm based on plasma metabolic fingerprint.

Authors:  Michal Ciborowski; Joanna Teul; Jose Luis Martin-Ventura; Jesús Egido; Coral Barbas
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

9.  Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models.

Authors:  Mohamed M Sayed-Ahmed; Meshan Lafi Aldelemy; Mohamed M Hafez; Othman A Al-Shabanah
Journal:  Oxid Med Cell Longev       Date:  2012-05-30       Impact factor: 6.543

10.  Downregulation of oxidative and nitrosative apoptotic signaling by L-carnitine in Ifosfamide-induced Fanconi syndrome rat model.

Authors:  Mohamed M Sayed-Ahmed; Mohamed M Hafez; Meshan Lafi Aldelemy; Abdulaziz M Aleisa; Salem S Al-Rejaie; Khaled A Al-Hosaini; Naif O Al-Harbi; Mohamed M Al-Harbi; Othman A Al-Shabanah
Journal:  Oxid Med Cell Longev       Date:  2012-11-13       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.